Neurizon Therapeutics Limited has released a press release.
Key Appointment to Progress MPL COVID-19 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Appendix 4D & Half Year Report
- Epichem Confirms Effectiveness of OHD E-Waste Project
- Update on Manufacture of MPL & Tablets for Clinical Trials
- Epichem Awarded Contract Extension from DNDi
- Shareholder Update - Progress and Strategy
Later from Neurizon Therapeutics
- Preliminary MPL antiviral leukaemia preclinical WEHI results
- MPL manufactured and tableting commenced
- PAA appoints trial manager & receives $200k from FightMND
- PharmAust Receives $708k R&D Tax Incentive Refund
- PharmAust Expands Lymphoma Canine Trial to the USA
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics